内部控制自我评价报告的核查意见 华泰联合证券有限责任公司 关于华兰生物疫苗股份有限公司 2024 年度内部控制自我评价报告的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为华 兰生物疫苗股份有限公司（以下简称"华兰疫苗"、"公司"或"发行人"）首次公开 发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等文件的要求，华泰联合对华兰疫苗 2024 年度内部控制制度等相关事项进行核 查，并发表独立意见如下： 一、华兰疫苗内部控制的基本情况 （一）内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风 险领域。 纳入评价范围的公司包括公司本部及下属子公司，纳入评价范围单位资产占 公司合并财务报表资产总额的 100%，营业收入合计占公司合并财务报表营业收 入总额的 100%。 纳入评价范围的主要业务和事项包括: 组织结构、公司治理、发展战略、人 力资源政策、公司对子公司的内部控制、关联交易的内部控制、财务报告、对外 担保控制、对外投资控制、信息披露管理等。 （二 ...

Financial Performance - The company's operating revenue for 2024 was ¥1,127,812,323.85, a decrease of 53.21% compared to ¥2,410,428,457.20 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥205,515,315.75, down 76.10% from ¥859,968,598.42 in 2023[21]. - The cash flow from operating activities for 2024 was ¥468,041,442.48, a decline of 47.29% compared to ¥888,024,961.36 in 2023[21]. - The basic earnings per share for 2024 was ¥0.3436, a decrease of 76.00% from ¥1.4316 in 2023[21]. - The total assets at the end of 2024 were ¥7,523,255,843.58, down 5.90% from ¥7,995,318,297.21 at the end of 2023[21]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, with a decrease of 84.12% to ¥120,390,566.59 in 2024 from ¥757,997,173.80 in 2023[21]. - The company is experiencing uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the last three accounting years[21]. - The company's total revenue for 2024 was approximately ¥1.13 billion, a decrease of 53.21% compared to ¥2.41 billion in 2023[47]. - Vaccine products accounted for 99.59% of total revenue in 2024, with a revenue of approximately ¥1.12 billion, down 53.34% from ¥2.41 billion in 2023[47]. - The influenza vaccine generated approximately ¥1.07 billion in revenue, representing 95.14% of total revenue from vaccine products, a decline of 55.34% year-over-year[48]. Market Conditions and Risks - The company's performance in 2024 significantly declined due to multiple factors, including a decrease in flu vaccine prices, fluctuations in vaccination rates, and a drop in market demand, with many vaccine companies reporting a decline of over 50% in their annual performance[5]. - Despite the challenging market environment, the company does not foresee significant risks to its ongoing operations, as there is no indication of overcapacity or sustained decline in the industry[5]. - The company has detailed potential risks in its report, which investors should review to understand the differences between plans, forecasts, and commitments[6]. - The overall trend of performance fluctuations aligns with the broader industry trends, as multiple domestic vaccine companies have experienced similar challenges[5]. - The competitive landscape for quadrivalent influenza vaccines is intensifying, with price reductions from multiple manufacturers potentially affecting market share and profitability[84]. - The company faces risks related to its product structure being relatively singular, with over 90% of revenue coming from influenza vaccines, which could impact profitability if market conditions change[82]. - The company faces risks in vaccine development due to lengthy approval processes and potential delays that could impact revenue generation[83]. Research and Development - The company continues to focus on research and development of new products and technologies to enhance its market position[5]. - The company is actively developing an mRNA vaccine research platform to prepare for future technological advancements in vaccine development[42]. - Research and development expenses increased by 78.51% to approximately ¥162.64 million, primarily due to increased clinical trial costs[56]. - The company has ongoing clinical research and registration for several vaccines, including a four-valent influenza vaccine and a rabies vaccine, with plans to expand its product pipeline[43]. - The company has established several core technology platforms to enhance vaccine research and production capabilities, aiming to mitigate product development risks[84]. Product Development and Market Strategy - The company has obtained drug registration certificates for various vaccines, including the quadrivalent influenza vaccine and the recombinant hepatitis B vaccine, establishing a strong position in the influenza vaccine sector[34]. - The company is preparing for production registration of the freeze-dried ACYW135 meningococcal polysaccharide vaccine, which has completed Phase III clinical trials[37]. - The company plans to reduce the price of the quadrivalent influenza vaccine by approximately 30% in June 2024 to enhance market competitiveness and accessibility[36]. - The company aims to improve the efficiency of fund utilization, achieving a usage rate of 56.31% for the raised funds[69]. - The company plans to enhance its marketing network to support the sales of existing products and the market introduction of new products, emphasizing the need for a more professional sales team[80]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[99]. Governance and Compliance - The company maintains a commitment to transparency and accuracy in its financial reporting, as affirmed by its board and management[5]. - The company has established a comprehensive internal control system and has maintained effective financial reporting internal controls with no significant deficiencies identified during the reporting period[133]. - The internal control audit report confirmed that the company maintained effective financial reporting internal controls as of December 31, 2024, with a standard unqualified opinion issued[137]. - The company has a strong governance structure, ensuring compliance with legal requirements and protecting shareholder interests[91]. - The company has implemented a transparent process for recommending board candidates, ensuring no interference in personnel decisions made by the board and shareholders[95]. Shareholder Engagement and Remuneration - The company plans to implement a stock repurchase program to stabilize its stock price within three years of its IPO, with a maximum repurchase amount not exceeding 30% of the previous year's audited net profit attributable to shareholders[156]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 192.77 million RMB[111]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation to company performance[131]. - The company ensured that minority shareholders had sufficient opportunities to express their opinions and that their rights were adequately protected[127]. - The company held its annual general meeting with an investor participation rate of 83.30% on April 19, 2024, and a temporary shareholders' meeting with a participation rate of 81.15% on August 9, 2024[97]. Social Responsibility and Community Engagement - The company emphasizes the integration of economic and social benefits, aiming for harmonious development with society while ensuring shareholder returns[144]. - The company actively engages in social responsibility initiatives, including targeted assistance in rural revitalization efforts[146]. - The company is committed to maintaining high standards in quality assurance and regulatory compliance in its operations[104]. - The company has pledged to continue its commitment to public welfare and community support as part of its operational strategy[144].

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-014 华兰生物疫苗股份有限公司 关于续聘公司2025年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司(以下简称"公司")于 2025 年 3 月 28 日召开第二届 董事会第十三次会议，审议通过了《关于续聘公司 2025 年度审计机构的议案》。拟 续聘大华会计师事务所（特殊普通合伙）（以下简称"大华"）为公司 2025 年度审计 机构。本事项尚需公司股东大会审议通过，现将有关事宜公告如下： 一、拟续聘会计师事务所的基本情况 1、基本信息 机构名称：大华会计师事务所（特殊普通合伙） 成立日期：2012 年 2 月 9 日成立（由大华会计师事务所有限公司转制为特殊普 通合伙企业） 组织形式：特殊普通合伙 注册地址：北京市海淀区西四环中路 16 号院 7 号楼 1101 首席合伙人：梁春 截至 2024 年 12 月 31 日合伙人数量：150 人 截至 2024 年 12 月 31 日注册会计师人数：887 人，其中：签署过证券服务业务 审计报告的注册会计 ...

华兰生物疫苗股份有限公司 关于继续使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司（以下简称"公司"或"华兰疫苗"）于2025年2月28日 召开了第二届董事会第十二次会议、第二届监事会第十次会议，审议通过了《关于 继续使用部分闲置募集资金进行现金管理的议案》，同意在确保不影响募集资金投 资项目建设和公司正常生产经营的前提下，继续使用不超过人民币10亿元闲置募集 资金进行现金管理，现金管理有效期自董事会审议通过之日起12个月内有效。在上 述额度和期限内，资金可循环滚动使用。现将具体情况公告如下： 一、募集资金基本情况 证券代码：301207 证券简称：华兰疫苗 公告编号：2025-006 根据中国证券监督管理委员会《关于同意华兰生物疫苗股份有限公司首次公开 发行股票注册的批复》（证监许可〔2022〕2号），公司获准向社会公开发行人民币 普通股（A股）股票4,001.00万股，每股面值人民币1元，发行价格为人民币56.88元 /股，募集资金总额为人民币2,275,768,800.00元，扣除各项发行费 ...

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-005 华兰生物疫苗股份有限公司 第二届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 经审议，监事会认为：在确保不影响募集资金项目建设进度和公司正常经营的 情况下，通过适度的现金管理，可以提高资金的使用效率，获得一定的投资收益， 为公司股东谋求更多的投资回报。全体监事一致同意本次关于使用部分闲置募集资 金进行现金管理的事项。 保荐机构就本议案发表了无异议的核查意见。 具体内容详见公司同日披露于巨潮资讯网的《关于继续使用部分闲置募集资金 进行现金管理的公告》（公告编号：2025-006）。 三、备查文件 第二届监事会第十次会议决议。 特此公告。 一、监事会会议召开情况 华兰生物疫苗股份有限公司（以下简称"公司"）第二届监事会第十次会议于2025 年2月20日以电话或网络通讯方式发出通知，于2025年2月28日以现场方式召开。本 次会议由监事会主席娄源成先生召集并主持，会议应出席监事3名，实际出席监事3 名。会议的召集和召开符合《公司法》和《公司章程》的有关规定。 二、监事 ...

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-004 一、董事会会议召开情况 华兰生物疫苗股份有限公司（以下简称"公司"）第二届董事会第十二次会议于 2025年2月20日以电话或网络通讯方式发出通知，于2025年2月28日以现场结合通讯 表决方式召开，会议应出席董事9名，实际出席董事9名。会议的召集和召开符合《公 司法》和《公司章程》的有关规定。 二、董事会会议审议情况 会议以9票同意，0票反对，0票弃权的表决结果审议通过了《关于继续使用部 分闲置募集资金进行现金管理的议案》。 华兰生物疫苗股份有限公司 第二届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 具体内容详见公司同日披露于巨潮资讯网的《关于继续使用部分闲置募集资金 进行现金管理的公告》（公告编号：2025-006）。 三、备查文件 1、第二届董事会第十二次会议决议； 2、第二届董事会第三次独立董事专门会议决议。 特此公告。 同意公司在确保不影响募集资金投资项目建设和公司正常生产经营的前提下， 继续使用不超过人民币10亿元闲置募集资金进行现金管理，现金管理 ...

关于华兰生物疫苗股份有限公司 继续使用部分闲置募集资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为华兰生物疫苗股份有限公司（以下简称"华兰疫苗"或"公司"）首次公开 发行股票并在创业板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业 务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等规定，对华兰疫苗拟继续使 用部分闲置募集资金进行现金管理的事项进行了审慎尽职调查，具体情况如下： 一、募集资金基本情况 核查意见 华泰联合证券有限责任公司 根据中国证券监督管理委员会《关于同意华兰生物疫苗股份有限公司首次公 开发行股票注册的批复》（证监许可〔2022〕2 号），华兰疫苗获准向社会公开 发行人民币普通股（A 股）4,001.00 万股，每股面值人民币 1 元，发行价格为 56.88 元/股，募集资金总额为人民币 2,275,768,800.00 元，扣除各项发行费用人民币 31,565,696.07 元（含税），实际 ...

Investment Rating - The report upgrades the investment rating of the company to "Accumulate" [5][11] Core Views - The company is expected to see a significant improvement in performance in 2025 after a disappointing 2024, where net profit is projected to drop by 70.93% to 76.74% compared to the previous year [7][5] - The main revenue source, the influenza vaccine, faced a price reduction of over 40% in June 2024, impacting sales and overall profitability [7][5] - Despite the challenges, the company continues to invest in innovative vaccine development and maintain a high level of R&D expenditure [7][5] Financial Summary - Revenue for 2024 is estimated at 1,600 million, a decrease of 33.62% from 2023, with a projected recovery to 2,200 million in 2025 [5][8] - Net profit for 2024 is expected to be between 215 million and 250 million, a significant decline from 860 million in 2023, but is forecasted to rebound to 806 million in 2025 [5][8] - Earnings per share (EPS) are revised down to 0.36 for 2024, with expectations of 1.34 and 1.23 for 2025 and 2026 respectively [5][8]

Financial Performance - The company expects a net profit for 2024 to be between 200 million and 250 million CNY, representing a decline of 70.93% to 76.74% compared to the previous year's profit of 859.9686 million CNY [3]. - The net profit after deducting non-recurring gains and losses is projected to be between 110 million and 160 million CNY, down 78.89% to 85.49% from last year's 757.9972 million CNY [3]. - Non-recurring gains and losses are expected to impact net profit by approximately 90 million CNY, primarily from investment income generated from idle funds [6]. Market and Sales Impact - The business development and profitability have been significantly impacted by changes in vaccination rates, declining market demand, and reduced sales [6]. - The company adjusted the price of its quadrivalent influenza vaccine by over 40% in June 2024 to enhance market competitiveness and accessibility [5]. Research and Development - The company maintains a high level of investment in R&D for innovative vaccines and gene-engineered vaccines, which has negatively affected net profit [6].

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-001 华兰生物疫苗股份有限公司 第二届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华兰生物疫苗股份有限公司（以下简称"公司"）第二届董事会第十一次会议 于2025年1月3日以电话或网络通讯方式发出通知，于2025年1月10日以现场结合 通讯表决方式召开，会议应出席董事9名，实际出席董事9名。会议的召集和召开 符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 会议以9票同意，0票反对，0票弃权的表决结果审议通过了《关于指定董事 兼总经理代行董事会秘书及财务总监职责的议案》。 为保证公司日常运作等工作有序开展，公司董事会同意在正式聘任新的董事 会秘书及财务总监前，指定董事兼总经理安文珏女士代行董事会秘书及财务总监 职责。公司将按照相关法律法规尽快正式聘任董事会秘书及财务总监，并履行相 关信息披露义务。 公司审计委员会对本议案发表了一致同意的审议意见。 具体内容详见公司同日披露于巨潮资讯网的《关于公司董事会秘书兼财务总 监辞职暨指 ...